TG Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

TG Therapeutics

01/11/2023 13:32

* TG Therapeutics Inc  TGTX.OQ  reported quarterly adjusted
earnings of 73 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -26 cents.  The mean expectation of
seven analysts for the quarter was for earnings of 12 cents per
share. Wall Street expected results to range from -28 cents
to 62 cents per share.
    * Revenue rose 176,298.9% to $165.82 million from a year
ago;
analysts expected $46.56 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was 73
cents​.
    * The company reported quarterly net income of $113.93
million.
    * TG Therapeutics Inc shares had fallen by 7.5% this
quarter and
lost 34.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 478.6%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for TG Therapeutics
Inc is $24.00 
This summary was machine generated from LSEG data November 1 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      0.12           0.73           Beat
 Jun. 30 2023      -0.25          -0.34          Missed
 Mar. 31 2023      -0.37          -0.28          Beat
 Dec. 31 2022      -0.26          -0.39          Missed